PF-06459988

Cat. No.:	HY-19985			
CAS No.:	1428774-45-1			
Molecular Formula:	C ₁₉ H ₂₂ ClN ₇ O ₃			
Molecular Weight:	431.88			
Target:	EGFR			
Pathway:	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK			
Storage:	Powder	-20°C	3 years	
		4°C	2 years	
	In solvent	-80°C	2 years	
		-20°C	1 year	

SOLVENT & SOLUBILITY

In Vitro	DMSO : 50 mg/mL (115.77 mM; Need ultrasonic)						
	Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg		
		1 mM	2.3155 mL	11.5773 mL	23.1546 mL		
		5 mM	0.4631 mL	2.3155 mL	4.6309 mL		
		10 mM	0.2315 mL	1.1577 mL	2.3155 mL		
	Please refer to the sol	ubility information to select the ap	propriate solvent.				
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.75 mg/mL (6.37 mM); Clear solution						
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.75 mg/mL (6.37 mM); Clear solution						
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.75 mg/mL (6.37 mM); Clear solution						

Description	PF-06459988 is an orally activity, irreversible and mutant-selective inhibitor of EGFR mutant forms. PF-06459988 demonstrates high potency and specificity to the T790M-containing double mutant EGFRs. PF-06459988 can be used for the research of cancer ^[1] .
IC₅₀ & Target	IC50: 45 nM (H1975 EGFR), 3.3 μM (EGFR)
In Vitro	PF-06459988 (0-10 μ M; 2 h) shows good cellular potency to NSCLC cell lines and high selectivity between the potent target

Product Data Sheet

Ν

Ô

ĊL

•0

N⁼



and WT EGFR ^[1] . MCE has not independer Cell Cytotoxicity Assay ^[1]	ntly confirmed the accuracy of these methods. They are for reference only.]
Cell Line:	NSCLC cell lines
Concentration:	0-10 μΜ
Incubation Time:	2 hours
Result:	Exibited excellent cellular potency to H1975 (L858R/T790M), PC9-DRH (Del/T790M), H3255 (L858R), PC9 (Del), HCC827 (Del) and A549 (WT) cell lines with IC ₅₀ values of 13, 7, 21, 140, 90 and 5100 nM, respectively. Showed high specificity to T790M-containing double mutan EGFRs.

REFERENCES

[1]. Cheng H, et al. Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants. J Med Chem. 2016 Mar 10;59(5):2005-24. doi: 10.1021/acs.jmedchem.5b01633. Epub 2016 Jan 28.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA